Ikena Oncology Analyst Ratings
Ikena Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 787.1% | HC Wainwright & Co. | $18 → $11 | Maintains | Buy |
| 09/22/2023 | 787.1% | Wedbush | → $11 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 08/07/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/24/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/16/2023 | 948.39% | Credit Suisse | → $13 | Reiterates | Outperform → Outperform |
| 05/04/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Assumes | → Buy |
| 03/17/2023 | 1674.19% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 03/15/2023 | 948.39% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 11/29/2022 | 1190.32% | Credit Suisse | $18 → $16 | Maintains | Outperform |
| 11/29/2022 | 1674.19% | HC Wainwright & Co. | $26 → $22 | Maintains | Buy |
| 11/08/2022 | 1351.61% | Credit Suisse | $20 → $18 | Maintains | Outperform |
| 05/13/2022 | 1512.9% | Credit Suisse | $24 → $20 | Maintains | Outperform |
| 04/13/2022 | 1996.77% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 12/23/2021 | 1916.13% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 08/13/2021 | 2077.42% | Credit Suisse | $30 → $27 | Maintains | Outperform |
| 04/20/2021 | — | Jefferies | Initiates Coverage On | → Buy | |
| 04/20/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 04/20/2021 | 2319.35% | Credit Suisse | → $30 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/09/2023 | 787.1% | HC Wainwright & Co. | 18 美元 → 11 美元 | 維護 | 買 |
| 09/22/2023 | 787.1% | Wedbush | → 11 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 08/10/2023 | 1351.61% | HC Wainwright & Co. | → 18 美元 | 重申 | 購買 → 購買 |
| 08/07/2023 | 1351.61% | HC Wainwright & Co. | → 18 美元 | 重申 | 購買 → 購買 |
| 05/24/2023 | 1351.61% | HC Wainwright & Co. | → 18 美元 | 重申 | 購買 → 購買 |
| 05/16/2023 | 948.39% | 瑞士信貸 | → 13 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/04/2023 | 1351.61% | HC Wainwright & Co. | → 18 美元 | 假設 | → 購買 |
| 03/17/2023 | 1674.19% | HC Wainwright & Co. | → 22 美元 | 重申 | → 購買 |
| 03/15/2023 | 948.39% | 瑞士信貸 | 16 美元 → 13 美元 | 維護 | 跑贏大盤 |
| 2022 年 11 月 29 日 | 1190.32% | 瑞士信貸 | 18 美元 → 16 美元 | 維護 | 跑贏大盤 |
| 2022 年 11 月 29 日 | 1674.19% | HC Wainwright & Co. | 26 美元 → 22 美元 | 維護 | 買 |
| 2022 年 8 月 11 日 | 1351.61% | 瑞士信貸 | 20 美元 → 18 美元 | 維護 | 跑贏大盤 |
| 05/13/2022 | 1512.9% | 瑞士信貸 | 24 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 2022 年 4 月 13 日 | 1996.77% | HC Wainwright & Co. | 25 美元 → 26 美元 | 維護 | 買 |
| 12/23/2021 | 1916.13% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/13/2021 | 2077.42% | 瑞士信貸 | 30 美元 → 27 美元 | 維護 | 跑贏大盤 |
| 04/20/2021 | — | 傑富瑞集團 | 啓動覆蓋範圍開啓 | → 購買 | |
| 04/20/2021 | — | 威廉布萊爾 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 04/20/2021 | 2319.35% | 瑞士信貸 | → 30 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Ikena Oncology (IKNA)?
Ikena Oncology（IKNA）的目標價格是多少？
The latest price target for Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on November 9, 2023. The analyst firm set a price target for $11.00 expecting IKNA to rise to within 12 months (a possible 787.10% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月9日公佈了艾肯納腫瘤學（納斯達克股票代碼：IKNA）的最新目標股價。該分析公司將目標股價定爲11.00美元，預計IKNA將在12個月內升至12個月內（可能上漲787.10％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for Ikena Oncology (IKNA)?
分析師對Ikena Oncology（IKNA）的最新評級是多少？
The latest analyst rating for Ikena Oncology (NASDAQ: IKNA) was provided by HC Wainwright & Co., and Ikena Oncology maintained their buy rating.
HC Wainwright & Co. 對艾肯納腫瘤學（納斯達克股票代碼：IKNA）的最新分析師評級由HC Wainwright & Co. 提供，Ikena Oncology維持買入評級。
When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?
Ikena Oncology（IKNA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Ikena Oncology的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Ikena Oncology的最新評級是在2023年11月9日發佈的，因此您應該預計下一個評級將在2024年11月9日左右公佈。
Is the Analyst Rating Ikena Oncology (IKNA) correct?
分析師對 Ikena Oncology (IKNA) 的評級是否正確？
While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a maintained with a price target of $18.00 to $11.00. The current price Ikena Oncology (IKNA) is trading at is $1.24, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的艾肯納腫瘤學（IKNA）評級保持不變，目標股價爲18.00美元至11.00美元。Ikena Oncology（IKNA）目前的交易價格爲1.24美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。